RGTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RGTI is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants an immediate decision. The stock has momentum in the quantum theme, but the current pre-market dip, mixed analyst stance, high valuation risk, and lack of strong proprietary buy signals make it a hold rather than an outright buy.
Price is trading pre-market at 18.34, down 4.77%, which is below the pivot level of 18.878 and near support at 17.268. MACD histogram is still positive at 0.0853, but it is contracting, suggesting weakening upward momentum. RSI_6 at 56.1 is neutral, and moving averages are converging, which points to a cautious trend rather than a clean breakout. Overall, the technical setup is mixed and does not show a strong immediate entry.
Investor interest in quantum computing is rising, which supports sector momentum. Rigetti’s Q1 revenue tripled to $4.4 million, driven by University of Saskatchewan sales. Analysts like Mizuho and Benchmark still see upside and continue to rate the stock Outperform or Buy, and benchmark commentary highlighted confidence in the company’s technology trajectory and strategic positioning. The company also continues progress on its superconducting roadmap and 108-qubit system deployment.
The stock fell after the latest quarter because operating expenses increased sharply. Recent news also notes revenue declined in 2025 and net losses remain significant, reinforcing financial weakness. Mizuho cut its price target from $33 to $27, and Northland initiated at Market Perform with a $20 target, showing a mixed analyst backdrop. The stock’s valuation remains difficult to justify given ongoing losses, and the pre-market drop reflects immediate selling pressure.
Latest quarter: Q1 2026. Revenue tripled to $4.4 million, which is strong top-line growth, but that growth came alongside rising operating expenses and continued net losses. The latest quarter shows improving commercial traction, but profitability is still far from established, and the company remains in an early-stage growth-and-burn phase.
Analyst sentiment is mixed but still slightly positive overall. Mizuho lowered its price target to $27 from $33 and kept an Outperform rating, while Benchmark kept Buy but lowered its target to $25 from $35. Northland initiated coverage at Market Perform with a $20 target, and Jefferies has a Hold rating with a $20 target. The trend in price targets is clearly downward, indicating pros still like the story but are trimming expectations. Wall Street pros view: long-term quantum upside remains compelling. Cons view: execution risk, losses, and sector malaise are still major concerns. No recent politician or influential figure buying or selling was reported, and there is no recent congress trading data.
